This segment addresses one of the most pressing challenges in advanced SCAC: management after progression on first-line carboplatin, paclitaxel, and retifanlimab.
Marwan G. Fakih, MD
Articles by Marwan G. Fakih, MD
This segment addresses 2 key clinical questions following the adoption of chemo-immunotherapy in advanced SCAC: which patients benefit most and how long treatment should be continued.
This segment focuses on the durability of benefit with first-line chemo-immunotherapy in advanced SCAC and how the POD1UM-303 findings are shaping real-world treatment decisions.
PODIUM-03 shows retifanlimab plus carboplatin/paclitaxel boosts response and survival, reshaping first-line care for advanced anal cancer.
Explore rising HPV-driven anal cancer burden and NCCN first-line choices, with trial data guiding chemo-immunotherapy patient selection.
Marwan G. Fakih, MD, discusses barriers that create treatment differences in metastatic colorectal cancer for community oncologists.
John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal cancer.
Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.
Marwan G. Fakih, MD, discusses topics in metastatic colorectal cancer from the Case-Based Roundtable meeting he moderated.
Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in microsatellite stable metastatic colorectal cancer without liver metastases.
Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.
Marwan G. Fakih, MD, provides an overview of the study design, rationale, and findings from a phase 2 trial of balstilimab with botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.
